BELTSVILLE, MD--(Marketwire - August 11, 2008) - BioServe today announced that it has been selected by the Fairbanks Institute for Healthy Communities to process all biological samples from the Indiana Health Study, a new landmark longitudinal study of coronary artery disease. The Indiana Health Study is a community-based research initiative using the population of Indianapolis and surrounding areas as study participants to create a research platform that will lead to the development of new drugs and diagnostics for chronic diseases such as heart disease, cancer and diabetes.

Coronary artery disease is the leading cause of death in the nation and claims the lives of more than 340,000 Hoosiers each year. The Indiana Health Study gives the community a chance to participate in the improvement of their own health.

Sponsored by the Fairbanks Institute for Healthy Communities, an Indianapolis-based nonprofit organization, the Indiana Health Study will create one of the nation's most comprehensive resources for academic and commercial research by integrating Indiana-sourced biological samples such as serum, DNA, plasma and RNA, along with medical data and lifestyle information collected from two cohorts of people: patients with coronary artery disease and people without the disease. The Indiana Health Study takes advantage of the internationally recognized health informatics capabilities of the Regenstrief Institute at Indiana University. Retrospective and prospective medical information will be collected on study participants via the Regenstrief Medical Records System, one of the nation's first electronic medical record systems.

"The Fairbanks Institute is committed to collecting, processing and storing all biological samples for this study under conditions that produce the highest quality samples," stated Dr. Cynthia Helphingstine, President and COO. "We chose BioServe as our partner for the processing of our biological samples based on their proven ability to process biological samples at the level of quality required in discovery research today.

"BioServe's experience with processing many different types of biological materials using standardized protocols in a CLIA-certified laboratory is essential to providing researchers with samples that are of the quality necessary to disentangle the genetic, lifestyle and environmental determinants of chronic disease."

Dr. Kevin Krenitsky, Chief Executive Officer of BioServe, stated, "The Fairbanks Institute is at the cutting edge of a growing effort to provide medical researchers with biological samples connected to detailed longitudinal clinical information for many types of research studies. We are excited to play an integral role in this novel health study and contribute to the ability of researchers to develop new diagnostics and drugs that will improve the clinical management of chronic diseases such as cancer, heart disease and diabetes."

Indianapolis is an ideal site for gathering robust health information for community-based research. It is a diverse community, which is representative of the national census, a health-challenged population (ranking high on national lists for cardiovascular disease, cancer, diabetes and other illnesses) and has a stable residency making subject follow up possible. In addition, the population's health challenges have been studied and well documented since the early 1970s through the Regenstrief Institute.

About Fairbanks Institute for Healthy Communities

Formed with a $10 million gift from the Richard M. Fairbanks Foundation and the collaboration of BioCrossroads, Indiana University School of Medicine, Regenstrief Institute and other Indianapolis community health leaders, Fairbanks Institute is creating one of the nation's most comprehensive resources for finding better ways to prevent, diagnose and treat the nation's most common, chronic diseases. Through the Indiana Health Study, the Fairbanks Institute is assembling and maintaining a collection of biological samples and linked clinical and disease-specific information collected from the population of Indianapolis for academic and commercial research use.

About BioServe

BioServe is a leader in the processing, development, and validation of diagnostic tests for the practice of personalized, predictive and preventive medicine. Leading pharma, biotech and diagnostic firms collaborate with BioServe to identify and validate markers that cause disease while correlating clinical and molecular data to develop new diagnostic tests promoting wellness around the world. BioServe offers the Global Repository®, a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients from four continents. Leveraging BioServe's robust genomic analytical services, technology, Global Repository and CLIA-certified laboratory, collaborators gain a complete, highly efficient platform for processing diagnostic test results and identifying genomic markers for powerful new assays. BioServe has headquarters in Beltsville, MD and Hyderabad, India. For more information please visit or call 301-470-3362.

Contact Information: Contacts: Kevin Krenitsky Chief Executive Officer BioServe 301-470-3362 Constantine Theodoropulos Boston Communications 617-292-7319